Labl Inc, founded in 2010 and based in San Francisco, aims to revolutionize the retail medical laboratory industry through innovative diagnostic solutions. The company offers a diverse range of services, including genetic testing, laboratory automation, and telehealth integration, catering to both healthcare providers and patients.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| LABL 5.88% 2028-11-01 USDLabl Inc | United States | 2028-11-01 | 5.875 | 14.25 |
| LABL 5.88% 2028-11-01 USDLabl Inc | United States | 2028-11-01 | 5.875 | 14.29 |
| LABL 8.25% 2029-11-01 USDLabl Inc | United States | 2029-11-01 | 8.250 | 22.08 |
| LABL 8.25% 2029-11-01 USDLabl Inc | United States | 2029-11-01 | 8.250 | 21.40 |
| LABL 8.63% 2031-10-01 USDLabl Inc | United States | 2031-10-01 | 8.625 | 15.78 |
| LABL 9.50% 2028-11-01 USDLabl Inc | United States | 2028-11-01 | 9.500 | 16.24 |
| LABL 9.50% 2028-11-01 USDLabl Inc | United States | 2028-11-01 | 9.500 | 16.24 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Labl Inc started issuing bonds in 2015 to fund its expansion into new markets, with a notable $100 million bond issuance in 2020 to support its cutting-edge laboratory technology advancements. Currently, Labl's bonds yield 5.5%, slightly above the industry average of 5.0%, attracting investors interested in reliable returns. Special features of Labl's bonds include call options and green certifications, responding to increased investor demand for sustainability. Recent news highlights a successful refinancing of existing debt which is expected to bolster its financial position further.